What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Area of Science:

• Immunology
• Allergy and Asthma
• Hematology

Background:

• Eosinophilic disorders are a diverse group of diseases characterized by elevated eosinophils.
• Eosinophils can range from minor participants to primary drivers of tissue damage in these conditions.
• Polyclonal eosinophil expansion is often driven by interleukin-5 from Th2 cells and ILC2s.

Purpose of the Study:

• To review the role of thymus and activation-regulated chemokine (TARC/CCL17) in type 2 immunity.
• To examine the clinical relevance of the TARC/CCL17-CCR4 axis in eosinophilic disorders.
• To explore the diagnostic, prognostic, and therapeutic potential of targeting this axis.

Main Methods:

• Literature review focusing on TARC/CCL17 and CCR4 in eosinophilic disorders.
• Analysis of the role of leukocyte recruitment in type 2 immune responses.
• Examination of clinical data related to the TARC/CCL17-CCR4 axis.

Main Results:

• TARC/CCL17 is a key chemo-attractant molecule involved in type 2 immunity.
• The TARC/CCL17-CCR4 axis plays a significant role in various eosinophilic disorders.
• Activation of this axis has potential diagnostic, prognostic, and therapeutic implications.

Conclusions:

• The TARC/CCL17-CCR4 axis is critically involved in the pathogenesis of eosinophilic disorders.
• Targeting the TARC/CCL17-CCR4 pathway presents a promising avenue for novel therapeutic interventions.
• Further research into this axis could lead to improved diagnostic and prognostic tools for eosinophilic diseases.